dc.contributor.author | Liposits, Gabor | |
dc.contributor.author | Skuladottir, Halla | |
dc.contributor.author | Ryg, Jesper | |
dc.contributor.author | Winther, Stine Brændegaard | |
dc.contributor.author | Möller, Sören | |
dc.contributor.author | Hofsli, Eva | |
dc.contributor.author | Shah, Carl-Henrik | |
dc.contributor.author | Poulsen, Laurids Østergaard | |
dc.contributor.author | Berglund, Åke | |
dc.contributor.author | Qvortrup, Camilla | |
dc.contributor.author | Osterlund, Pia | |
dc.contributor.author | Johansen, Julia S. | |
dc.contributor.author | Glimelius, Bengt | |
dc.contributor.author | Sorbye, Halfdan | |
dc.contributor.author | Pfeiffer, Per | |
dc.date.accessioned | 2023-01-11T10:19:27Z | |
dc.date.available | 2023-01-11T10:19:27Z | |
dc.date.created | 2022-10-30T13:11:15Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 2077-0383 | |
dc.identifier.uri | https://hdl.handle.net/11250/3042641 | |
dc.description.abstract | Appropriate patient selection for palliative chemotherapy is crucial in patients with metastatic colorectal cancer (mCRC). We investigated the prognostic value of C-reactive protein (CRP), derived neutrophil-to-lymphocyte ratio (dNLR), Interleukin (IL)-6, and YKL-40 on progression-free survival (PFS) and overall survival (OS) in the NORDIC9 cohort. The randomized NORDIC9-study included patients ≥70 years with mCRC not candidates for standard full-dose combination chemotherapy. Participants received either full-dose S1 (Teysuno) or a dose-reduced S1 plus oxaliplatin. Blood samples were collected at baseline and biomarkers were dichotomized according to standard cut-offs. Multivariable analyses adjusted for age, sex, ECOG performance status, and treatment allocation; furthermore, C-statistics were estimated. In total, 160 patients with a median age of 78 years (IQR: 76–81) were included between 2015 and 2017. All investigated biomarkers were significantly elevated in patients with either weight loss, ≥3 metastatic sites, or primary tumor in situ. In multivariable analyses, all markers showed significant association with OS; the highest HR was observed for CRP (HR = 3.40, 95%CI: 2.20–5.26, p < 0.001). Regarding PFS, statistically significant differences were found for CRP and IL-6, but not for dNLR and YKL-40. Applying C-statistics, CRP indicated a good prognostic model for OS (AUC = 0.72, 95%CI: 0.67–0.76). CRP is an easily available biomarker, which may support therapeutic decision-making in vulnerable older patients with mCRC. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, dNLR, YKL-40, and IL-6) in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy—The Randomized NORDIC9-Study | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
dc.source.articlenumber | 5603 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3390/jcm11195603 | |
dc.identifier.cristin | 2066439 | |
dc.source.journal | Journal of Clinical Medicine | en_US |
dc.identifier.citation | Journal of Clinical Medicine. 2022, 11 (19), 5603. | en_US |
dc.source.volume | 11 | en_US |
dc.source.issue | 19 | en_US |